Venetoclax plus Hypomethylating Agents versus Intensive Chemotherapy as Induction Therapy for Newly Diagnosed AML Patients with NPM1/FLT3-ITD/DNMT3A Triple Mutations: A Real-World, Multicenter Analysis Run title: VEN-HMA vs IA as induction therapy for AML patients with NPM1, FLT3-ITD and DNMT3A mutations

Acute myeloid leukemia is a disease where the bone marrow, the soft tissue inside our bones that makes blood, becomes flooded with immature, non-functioning white blood cells. These rogue cells crowd out the healthy ones, leaving the body unable to fight infection or stop bleeding. For decades, doctors have treated this condition with a standard approach: a powerful combination of chemotherapy drugs designed to wipe out the cancer and allow the marrow to start fresh. However, not all cases of this leukemia are the same. The disease is shaped by specific changes in the genetic code of the cancer cells, known as mutations. Some of these changes act like a switch that makes the cancer cells more dependent on a specific survival protein, while others make them sensitive to a different kind of drug that alters how genes are read. When a patient carries a specific trio of these genetic changes, the disease tends to be particularly aggressive and difficult to control, leaving doctors searching for a better way to start treatment.

Researchers in China recently set out to test a new strategy for patients with this specific, high-risk genetic profile. They focused on a group of people whose leukemia cells carried three distinct mutations: NPM1, FLT3-ITD, and DNMT3A. For these patients, the traditional path has been intensive chemotherapy, a regimen known as "7+3" that uses high doses of drugs over a week to force the body into a state of remission. The alternative being tested was a newer combination involving a drug called venetoclax, which blocks that specific survival protein the cancer cells rely on, paired with hypomethylating agents, a class of drugs that help the cancer cells behave more like normal cells and die. The question was whether this gentler, targeted combination could work as well as, or better than, the heavy-hitting traditional chemotherapy for this difficult group of patients.

To find the answer, a team of doctors from three hospitals analyzed the medical records of seventy-nine patients who had just been diagnosed with this triple-mutated leukemia between 2018 and 2023. The researchers did not assign patients to groups randomly; instead, they looked back at who had received which treatment based on what their doctors decided at the time. This created two groups for comparison: forty-five patients who received the traditional intensive chemotherapy and thirty-four who received the venetoclax combination. The researchers noticed a clear difference between the two groups before the treatment even began. The patients receiving the venetoclax combination were, on average, older and in poorer physical condition than those receiving the traditional chemotherapy. This is a crucial detail because doctors often choose gentler treatments for patients who are too frail to withstand the harsh side effects of standard chemotherapy.

When the researchers looked at how well the treatments worked, the results were striking. A significantly higher percentage of patients in the venetoclax group achieved a complete remission, meaning their bone marrow returned to a state where no cancer cells could be detected. Specifically, about seventy-two percent of the patients on the new combination reached this state, compared to only about forty-four percent of those on the traditional chemotherapy. Beyond just clearing the visible cancer, the venetoclax group also showed a deeper level of success. The researchers measured the amount of genetic material from the leukemia in the patients' blood and found that those on the venetoclax combination saw a much sharper drop in these cancer markers. More than half of the patients in the new group saw their cancer markers fall by a factor of ten or more, a level of reduction that was much harder to achieve with the traditional drugs.

Safety was another major factor in the comparison. Intensive chemotherapy is known for being brutal on the body, often causing severe infections and requiring long hospital stays. The study found that the patients receiving the venetoclax combination experienced fewer of these severe, life-threatening side effects. While both groups suffered from the expected drop in blood counts, the group on the new treatment had a much lower rate of severe fevers and infections linked to the treatment. This suggests that the venetoclax combination is not only effective at killing the cancer but also gentler on the patient, a vital consideration for the older, frailer individuals who often make up this specific patient group.

Despite these early successes, the story of long-term survival is more complex. The researchers tracked the patients for several years to see if the better initial response translated into living longer. At the three-year mark, the survival rate for the venetoclax group was higher than for the chemotherapy group, but the difference was not large enough to be considered statistically certain. The study was too small to say with absolute confidence that one treatment definitively saves more lives than the other in the long run. However, the data did reveal something else important: the speed and depth of the initial response mattered. Patients who did not see a rapid, significant drop in their cancer markers after the first round of treatment had a much harder time surviving, regardless of which drug they took. This suggests that how quickly the cancer retreats in the first few weeks is a powerful predictor of the future.

The study also highlighted the role of other genetic factors. The presence of a specific mutation called WT1 was linked to a poorer outcome, while receiving a stem cell transplant after the initial treatment was linked to a better chance of survival. The researchers noted that because the study was retrospective and the groups were not perfectly matched, the results should be viewed as a strong signal rather than a final verdict. The patients who received the new treatment were older and sicker to begin with, which makes the fact that they did so well even more impressive.

Ultimately, this research suggests that for patients with this specific, high-risk form of leukemia, the combination of venetoclax and hypomethylating agents is a highly effective way to start treatment. It clears the cancer more often and more deeply than the traditional approach, with fewer severe side effects. While the study could not prove beyond doubt that it extends life compared to chemotherapy, the strong early results and the safer profile make it a compelling option, especially for those who cannot tolerate the rigors of standard intensive chemotherapy. The findings point toward a future where treatment is tailored not just to the disease, but to the specific genetic makeup of the patient and their ability to withstand the therapy.